Pay in 4 interest-free payments of $6.99 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Retatrutide (5mg-10mg), Triple Incretin Receptor Agonist Engineered Engagement of GLP-1, GIP, and Glucagon Receptors Introduction Engineered Engagement of GLP-1, GIP, and Glucagon Receptors Retatrutide is a synthetic 39-residue peptide engineered as a balanced agonist of three distinct class B G protein-coupled receptors: the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR)
The venture-backed group has raised a combined $2.8 billion in funding, reflecting the intense investor appetite in the category
Hypoxia-inducible factor-1 deficiency results in dysregulated erythropoiesis signaling and iron homeostasis in mouse development
Increased alternate splicing of Htr2c in a mouse model for Prader-Willi syndrome leads disruption of 5HT2C receptor mediated appetite
